A new qualitative study published on medRxiv offers critical insights into the lived experiences of patients diagnosed with hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The research highlights the numerous barriers these patients face, including delayed diagnoses, fragmented care, social stigma, and financial hardship.

Conducted by Michelle Liu and Matthew Loxton of the Blue Faery, the study introduces a novel three-part measurement framework to better understand patient experiences. Key areas identified include the role of patient education and self-advocacy, the use of medical records in care navigation, and the availability of integrated support services such as dietitians, palliative care providers, and mental health counselors.

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer-related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer-reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients with advanced disease to ultimately undergo partial hepatectomy or transplantation with curative intent.

Blue Faery: The Adrienne Wilson Liver Cancer Association announces the Blue Faery Award (BFA) for Excellence in Liver Cancer Research recipient. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), remains the third leading cause of cancer-related deaths worldwide. Blue Faery established the award to honor medical professionals conducting groundbreaking research to improve patient outcomes.

The winner, Dr. Mark Yarchoan, said, "I am deeply honored to receive the Blue Faery Award, which not only supports liver cancer research but also highlights the strength of the community driving progress in this field."